TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals has announced the dispatch of offer documents and letters to eligible shareholders as part of its non-renounceable pro-rata entitlement offer of new options. This offer, which allows existing shareholders to acquire new shares at a specified price, has seen an increase in the number of options available due to recent exercises by option holders. The offer is open until December 15, 2025, and aims to strengthen the company’s financial position, potentially impacting its market presence and providing growth opportunities for stakeholders.
More about Living Cell Technologies
Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialization. The company utilizes its proprietary AI platform, AlgoraeOS, to identify synergistic drug combinations and guide dose selection for preclinical development. Algorae also operates a commercialization business, AlgoraeRx, which sources, licenses, and supplies generic and specialty medicines in Australia and New Zealand. The company collaborates with research institutions and industry partners to expand patient access to high-quality medicines.
YTD Price Performance: 50.0%
Average Trading Volume: 3,394,140
Technical Sentiment Signal: Buy
Current Market Cap: A$25.33M
For an in-depth examination of 1AI stock, go to TipRanks’ Overview page.